CHU Amiens-Picardie - Site Sud
- Address
- Avenue René Laënnec, 80480 Salouel, France
CHU Amiens-Picardie - Site Sud: Advanced Oncology Research Center
CHU Amiens-Picardie - Site Sud is a distinguished clinical research center specializing in advanced cancer therapeutics and innovative treatment protocols. The center demonstrates particular expertise in conducting complex Phase 2 and Phase 3 clinical trials across multiple oncological conditions, with a strong focus on immunotherapy and targeted therapy approaches for high-risk malignancies.
- Advanced melanoma treatment, including adjuvant immunotherapy with anti-PD-1 monoclonal antibodies for high-risk Stage III disease
- Pancreatic ductal adenocarcinoma (PDAC) research, focusing on maintenance therapy strategies and personalized medicine approaches for locally advanced and metastatic disease
- Chronic myelogenous leukemia (CML) management, particularly investigating combination therapies for accelerated phase and myeloid blast crisis
The center's research portfolio reflects a commitment to addressing challenging oncological conditions with precision medicine strategies. Their participation in international collaborative trials, including EORTC Melanoma Group studies, positions them at the forefront of developing novel therapeutic combinations and biomarker-driven treatment approaches, particularly in HLA-typing and PDL1 expression analysis for patient selection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Amiens-Picardie - Site Sud
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Pembrolizumab Versus Placebo in High-Risk Stage III Melanoma Post-Resection: A Randomized, Double-Blind Phase 3 EORTC Trial | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jul 2015 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azacitidine | 1 | Unknown | 2019-06-19 | 2019-06-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.